- Ceapro completes another record-setting quarter for the highest quarterly revenues reported in Company's history
- Clinical program with avenanthramides as anti-inflammatory compound initiated
EDMONTON, ALBERTA--(Marketwired - Aug. 24, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30, 2016 and provided an overview of recent operational highlights.
Financial Highlights for the Second Quarter of 2016
Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated, "We are very pleased to have ended the second quarter of 2016 with these exceptional results. Of note, this is the fourth consecutive record-setting quarter that Ceapro has delivered and we aim to continue to excel in our high-value de-risked base business in cosmeceuticals, which has shown to be a proven result of the effectiveness of our business strategy."
Recent Corporate Highlights
"With the results from this quarter combined with the announcement of the renewal of a long-term agreement with our major distributor, Symrise AG, Ceapro has established a solid base for this tremendous year-over-year growth and for the long term," added Mr. Gagnon.
Expected Near-Term Milestones
Mr. Gagnon concluded, "Beyond these excellent financial results and while we will transfer the manufacturing operations to a new manufacturing facility during the second half of 2016, we will do our utmost to continue to develop our pipeline and execute our projects rigorously toward market expansion into the profitable nutraceutical and pharmaceutical sectors."
Financial Results for the Three Month and Six Month Periods Ended June 30, 2016
|Consolidated Statements of Net Income and Comprehensive Income|
|Quarters Ended June 30,||Six Months Ended June 30,|
|Revenue (note 15)||4,167,855||2,439,366||8,231,431||4,153,851|
|Cost of goods sold||1,153,517||690,229||2,383,280||1,612,615|
|Research and product development||(61,251||)||236,835||266,581||342,742|
|General and administration||524,858||629,225||1,020,504||1,431,158|
|Sales and marketing||643||3,506||2,829||6,673|
|Finance costs (note 14)||48,896||37,024||147,377||143,774|
|Income from operations||2,501,192||842,547||4,410,860||616,889|
|Other operating loss (note 13)||(143,587||)||(184,823||)||(319,279||)||(189,253||)|
|Income before tax||2,357,605||657,724||4,091,581||427,636|
|Current tax expense||36,090||-||(421,916||)||-|
|Deferred tax (expense) recovery||(757,897||)||-||(820,475||)||36,250|
|Income tax (expense) recovery||(721,807||)||-||(1,242,391||)||36,250|
|Total comprehensive income for the period||1,635,798||657,724||2,849,190||463,886|
|Net income per common share (note 20):|
|Weighted average number of common shares outstanding (note 20):|
|Consolidated Balance Sheets|
|June 30,||December 31,|
|Cash and cash equivalents||909,934||1,681,125|
|Inventories (note 4)||960,302||1,242,417|
|Prepaid expenses and deposits||117,489||259,560|
|Investment tax credits receivable||487,339||603,302|
|Licenses (note 5)||31,848||33,329|
|Property and equipment (note 6)||13,047,816||9,868,676|
|Deferred tax assets||326,578||1,258,674|
|LIABILITIES AND EQUITY|
|Accounts payable and accrued liabilities||1,906,688||2,005,611|
|Deferred revenue (note 9)||372,328||1,172,198|
|Current portion of long-term debt (note 7)||988,291||984,318|
|Convertible debentures (note 8)||914,569||872,355|
|Current portion of CAAP loan (note 11)||77,858||72,942|
|Income tax payable||200,840||95,180|
|Long-term debt (note 7)||1,758,369||2,277,186|
|CAAP loan (note 11)||254,484||235,529|
|Deferred tax liabilities||-||111,621|
|Share capital (note 10)||6,973,903||6,800,018|
|Equity component of convertible debentures (note 8)||106,200||106,200|
|Retained earnings (deficit)||2,789,942||(59,248||)|
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: Ceapro Inc.